Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 22nd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Kalaris Therapeutics Price Performance

NASDAQ KLRS opened at $2.03 on Friday. The firm has a market cap of $48.33 million, a P/E ratio of -1.00 and a beta of 0.42. The stock’s 50-day moving average is $2.95 and its 200-day moving average is $5.44. Kalaris Therapeutics has a one year low of $1.78 and a one year high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. Equities analysts anticipate that Kalaris Therapeutics will post -1.99 EPS for the current year.

Institutional Trading of Kalaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pale Fire Capital SE acquired a new stake in Kalaris Therapeutics during the second quarter worth approximately $161,000. Velan Capital Investment Management LP boosted its holdings in shares of Kalaris Therapeutics by 38.9% during the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after acquiring an additional 7,000 shares during the period. Sigma Planning Corp bought a new stake in shares of Kalaris Therapeutics during the second quarter worth approximately $41,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Kalaris Therapeutics during the second quarter worth approximately $122,000. Finally, BlackRock Inc. bought a new stake in shares of Kalaris Therapeutics during the second quarter worth approximately $222,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Kalaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases, a group of eye conditions that can lead to vision loss. The company’s research is aimed at addressing diseases in which abnormal blood-vessel growth or leakage damages the retina.

Kalaris Therapeutics’ lead investigational product candidate is KAL-101, an experimental therapy being developed for retinal diseases. The company is advancing KAL-101 through clinical development and evaluating its potential to provide a treatment option for patients with conditions requiring ongoing management of retinal vascular abnormalities.

The company’s activities primarily center on research, clinical development, and the potential commercialization of ophthalmic medicines.